RAPT Therapeutics, Inc. (RAPT) Operating Expenses (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Operating Expenses for 5 consecutive years, with $54.5 million as the latest value for Q4 2024.
- Quarterly Operating Expenses rose 63.97% to $54.5 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $136.1 million through Dec 2024, up 7.11% year-over-year, with the annual reading at $136.1 million for FY2024, 7.11% up from the prior year.
- Operating Expenses hit $54.5 million in Q4 2024 for RAPT Therapeutics, up from $19.8 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $54.5 million in Q4 2024 to a low of $13.8 million in Q2 2020.
- Historically, Operating Expenses has averaged $24.1 million across 5 years, with a median of $20.6 million in 2022.
- Biggest YoY gain for Operating Expenses was 63.97% in 2024; the steepest drop was 41.66% in 2024.
- Year by year, Operating Expenses stood at $14.4 million in 2020, then surged by 30.6% to $18.8 million in 2021, then soared by 30.02% to $24.4 million in 2022, then skyrocketed by 35.96% to $33.2 million in 2023, then skyrocketed by 63.97% to $54.5 million in 2024.
- Business Quant data shows Operating Expenses for RAPT at $54.5 million in Q4 2024, $19.8 million in Q3 2024, and $29.3 million in Q2 2024.